Targeted Oncology19m
Behind Durvalumab's FDA Approval: NIAGARA Trial in MIBC
Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...
Targeted Oncology22h
Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer
Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.
PipelineReview.com4h
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
Medical Marketing & Media17h
Rx Rundown: Novo Nordisk, Merck, Eli Lilly and more
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Advanced Cervical Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
Share Prices5h
AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...
The American Journal of Managed Care17h
Inebilizumab FDA Approved as First Treatment for IgG4-RD
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...